Mereo BioPharma Details Anti-TIGIT Study And Attracts US Investors
Raises $70m In Private Placement
Executive Summary
Mereo BioPharma’s completed private placement in the US will support clinical studies of its candidate immuno-oncology product etigilimab and a later-stage anti-sclerotin antibody product with potential in the treatment of brittle bone disease.
You may also be interested in...
Tech Transfer: BMS, Evotec Partner With Four UK Universities On Translational Research Efforts
The firms hope academic research can yield first-in-class therapies and spinout companies. Also, Yale unveils research alliances with three biotechs.
Mereo Licenses Setrusumab To Ultragenyx For Osteogenesis Imperfecta
Ultragenyx hopes to expand its bone disease franchise in a deal that frees up Mereo to focus on its anti-TIGIT immuno-oncology pipeline asset.
Merck Is Counting On Keytruda To Establish Its Anti-TIGIT Drug
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.